333 University Av., Suite 120
Sacramento, CA 95825
Ph: 916-929-8564
Fax: 916-929-4529

• Capital Nephrology Medical Group, Sacramento, Ca
  Nov 2001- Present

• Davita Alhambra Dialysis Clinic, Medical Director
  2008 - Present

• Davita Elk Grove Dialysis Clinic, Medical Director
  2005 - Present

• Davita West Elk Grove Dialysis Clinic, Medical Director
  2002 - Present

• Fellow, Department of Nephrology. UMDNJ-Robert Wood Medical School at Camden, Cooper Hospital/University Medical Center. Camden, New Jersey
  1999 - 2001

• Resident, Department of Internal Medicine. St. Barnabas Medical Center. Livingston, New Jersey
  1996 -1999

• Nephrology and Hemodialysis Training. Moscow Central Institute of Advanced Medical Studies. Moscow, Russia
  1992

• Nephrologist, Hospital # 10. Rostov-on-Don, Russia
  Mar 1992- 1993

• Internist,Railway Riga, Latvia
  1989 - Dec 1991

• Rostov Medical School, Rostov-on-Don, Russia. Degree: M.D. Graduated with Honors
  1982-1988

• Providing Primary Care services for ESRD patients
• Training in all aspects of Nephrological care including managing pre-ESRD patients
• Renal Replacement Therapies such as hemodialysis, peritoneal dialysis and CVVHD
• Performing pre-transplant evaluation and managing transplant patients

• Kidney Biopsy
• Placement of temporary catheters for hemodialysis

• Board Certified in Internal Medicine
  1999 - Present

• California Medical License
  1998 - Current

• Board Certified in Nephrology
  2001 - Present

• Patricia Mello, Margaret Franger, Ziad Boujaoude, Mark Adaimy, Dr. Gelfand, Jonathan Kass, Lawrence S.Weisberg. Am J Kidney Disease, 2004 Oct; 44(4):636-41. Night and Day proteinurea in patients with sleep apnea.

• B.Kaplan, M. Jacobs, G. Friedman, S. Geffner, N. Lyman, E. Gelfand, S. Mulgaonkar. Incidence of gastrointestinal cytomegalovirus in renal transplant recipients with abdominal pain on mycophenolate mofetil. Transplantation 65:12, S115, June 27, 1998.

• E. Gelfand, S. Juvvadi, I. Shapira, R.S Panush. Non-inflammatory myopathies: Identifiable and treatable causes of muscle disease. American College of Physicians Associated Competition, Long Branch, NJ, Jan 16-17,1998

• E. Gelfand, Edward Gurski, Olga Gotsman. Prognostic importance of the level of middle-molecular-weight substances in patients with myocardial infarction. Bulletin of Student’s Scientific Society, Rostov Medical Institute 1987, pg.48

• Alexander Kastanayan, E. Gelfand, Andrei Shishkov. Influence of the different methods of treatment on the hemodynamics in patients with unstable angina. Bulletin of Student’s Scientific Society, Rostov Medical Institute 1988, pg.74

• Sergi Korolkov, E Gelfand, Victor Nadel. Correlation between the level of middle-molecular-weight substances and complications of myocardial infarction. Bulletin of Student’s Scientific Society, Rostov Medical Institute, 1988 pg.86

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Hemodialysis. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase III, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients previously treated with Epogen. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase II, Randomized, Double-Blind Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy of XXX in Patients with Nephropathy Due to Type 2 Diabetes. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

Patient FOCUS Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase II Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Hemodialysis, or Do Not Require Dialysis and Previously Treated with Darbepoetin Alfa. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of XXX to Licensed Vaccine (Energix-B®) among Adults (18-75 years of age) with Chronic Kidney Disease (CKD). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Randomized Evaluation of Efficacy and Safety of XXX in Patients with Iron Deficiency Anemia and Impaired Renal Function. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase 2, Multicenter, Randomized, Double-Blind Study of the Safety, Clinical Activity and Pharmacokinetics of XXX Versus Placebo in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a XXX in Adults with Type 2 Diabetes and Overt Nephropathy. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Patients with Systemic Lupus Erythematosus (SLE). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

Observational Study in Patients with Chronic Kidney Disease and Type 2 Diabetes: Identifying Patients: Identifying Patients with Estimated GFR Between 15 and 30 mL/min/1.73m². Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

March 2011: QWC01-MN-01 – A Randomized, Placebo-Controlled, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN)
Sponsor: Questcor Pharmaceuticals, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, Matthew Mezger, MD, David Pai, MD and Rohit Kashyap, MD as sub-investigators

May 2011: 402-C-0903 – Bardoxolone Methyl Evaluation in patients with Chronic Kidney Disease and Type 2 Diabetes; The Occurrence of Renal Events (BEACON)
Sponsor: Reata Pharmaceuticals, Inc; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, Matthew Mezger, MD, David Pai, MD, Tarang Patel, MD, Stanley Ruggles, MD and Rohit Kashyap, MD as sub-investigators

August 2011: AFX01-18 – A Phase 3b Single-Arm, Conversion Study from Epoetin alfa to Monthly Peginesatide Injection in Patients with Chronic Kidney Disease on Dialysis.
Sponsor: Affymax, Inc; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, Matthew Mezger, MD, David Pai, MD, Tarang Patel, MD, Stanley Ruggles, MD and Rahit Kashyap, MD as sub-investigators

August 2011: EPOE-10-13 – A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospera and Epoetin Alfa (Amgen) in Patients with Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment.
Sponsor: Hospira, Inc.; Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

July 2012: ISG2012 – An Open Label Equivalence Study Comparing 50mg Weekly to 100mg Biweekly Maintenance Intravenous Iron Sucrose to Assess Impact in Ferritin, Transferrin Saturation, and Hemoglobin in Hemodialysis Patients
Sponsor: DaVita Clinical Research; Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators

October 2012: CTAP101-CL-3001 – A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Sponsor: Cytochroma, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, Matthew Mezger, MD, David Pai, MD and Rohit Kashyap, MD as sub-investigators

December 2012: ZS -003 – A Phase 3 Multicenter, Two-Phase, Multi-Dose, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia
Sponsor: ZS Pharma, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, Matthew Mezger, MD, David Pai, MD and Rohit Kashyap, MD as sub-investigators

January 2013: RLY5016-301 – A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Sponsor: Relypsa, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD as sub-investigators

May 2013: D5610C00001 – An Exploratory Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ASD1722 in CKD patients with Type 2 Diabetes Mellitus and Albuminuria
Sponsor: Ardelyx, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, and Matthew Mezger, MD as sub-investigators

May 2013: M11-352 – A Randomized, Multcountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy and Atrasentan
Sponsor: AbbVie Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD as sub-investigators

May 2013: KRX-0502-204 – A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects with Stage III to V Chronic Kidney Disease Not on Dialysis
Sponsor: Keryx Biopharmaceuticals; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, and Matthew Mezger, MD, as sub-Investigators

July 2013: CTAP101-CL-3003 - A Long-term Safety and Efficacy study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease Secondary Hyperparathyroidism and Vitamin D insufficiency (Extension Study CTAP101-CL-3001)
Sponsor: OPKO IP Holdings II, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD as sub-investigators

July 2013: MK-3102-019 - A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control
Sponsor: Merck; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ganesh Kambhampati, MD, Tarang Patel, MD, and Ratnaji Nallamothu MD as sub-investigators

August 2013: AKB-6548-CI-0007 – Phase 2b randomized, double-blind, placebo-controlled study to assess the Pharmacodynamic response, safety, and tolerability to 20 weeks of oral dosing of AKB-6548 in subjects with anemia secondary to chronic kidney disease (CKD), GFR categories G3A-G5 (Stages 3, 4 and 5) (Pre-dialysis)
Sponsor: Akebia therapeutics, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD as sub-investigators

October 2013: AMAG-FER-CKD-401: Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Sponsor: AMAG Pharmaceuticals, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, Ratnaji Nallamothu, MD, David Pai, MD, and Ganesh Kambhampati, MD as sub-Investigators.

Jan 2014: 2012-02-02-NVO-MIA Randomized Controlled Study of the Effect of a Needle Phobia Intervention With or Without Synera® on Conversion from Central Venous Catheters to Arteriovenous Fistula or Graft
Sponsor: DaVita Clinical Research; Naveen K. Atray, M.D. as PI; Dr. Gelfand, M.D., Ratnaji Nallamothu, M.D., Ganesh Kambhampati, M.D. as Sub-investigators

June 2014: VPI-CLN-201-AD: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes
Sponsor: Vascular Pharmaceuticals, Inc.; Naveen Atray, MD as PI; Dr. Gelfand, MD, and Ganesh Kambhampati, MD as sub-Investigators.

June 2014: D5613C00001 A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis
Sponsor: Astra Zeneca AB; Naveen K. Atray, M.D. as PI; Dr. Gelfand, M.D., David Pai, M.D., Ganesh Kambhampati, M.D. as Sub-investigators

June 2014: 28431754DNE3001-Phase 3 Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Sponsor: Janssen Research & Development; Naveen Atray, MD as PI; Dr. Gelfand, MD, and Ganesh Kambhampati, MD, as Sub-Investigators

August 2014: ZS-005 - A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), an Oral Sorbent, in Subjects With Hyperkalemia, Including a Randomized, Double-blind, Placebo-controlled, Withdrawal Study
Sponsor: ZS Pharma; Atray, MD as PI; Dr. Gelfand, MD, and Ganesh Kambhampati, MD, as Sub-Investigators

September 2014: KRX-0502-306 - A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects with Non-Dialysis Dependent Chronic Kidney Disease
Sponsor: Keryx Biopharmaceuticals, Inc; Naveen Atray, MD as PI; Dr. Gelfand, MD, and Ganesh Kambhampati, MD as sub-investigators

April 2015: D5740C00001 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Sponsor: Astra Zeneca: Ganesh Kambhampati, MD as PI; Naveen Atray, MD, Dr. Gelfand, MD as sub-investigators

June 2015: D5740C00002 - A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Sponsor: Astra Zeneca: Ganesh Kambhampati, MD as PI; Naveen Atray, MD, Dr. Gelfand, MD, David Pai, MD, Ratnaji Nallamothu, MD as sub-investigators